Forbion Portfolio Company, KaNDy Therapeutics, to Be Acquired by Bayer
Innovative non-hormonal oral compound NT-814 to alleviate menopausal symptoms Development compound recently completed Phase IIb Upfront consideration of USD 425 million and additional potential con…
